{
  "drugName": "Jaypirca",
  "setId": "bd551845-0878-49a4-860f-839b83f6b801",
  "slug": "jaypirca-bd55184",
  "labeler": "Lilly",
  "label": {
    "genericName": "pirtobrutinib",
    "labelerName": "Eli Lilly and Company",
    "productType": "HUMAN PRESCRIPTION DRUG LABEL",
    "effectiveTime": "20241113",
    "title": "JAYPIRCA",
    "indicationsAndUsage": "<section class=\"Section\" data-sectioncode=\"34067-9\"><a name=\"s1\"></a><a name=\"section-1\"></a><p></p><h1>1 INDICATIONS AND USAGE</h1><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s2\"></a><a name=\"section-1.1\"></a><p></p><h2>1.1 Mantle Cell Lymphoma</h2><p class=\"First\">JAYPIRCA<span class=\"Sup\">®</span> is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor.</p><p>This indication is approved under accelerated approval based on response rate <span class=\"Italics\">[see Clinical Studies (<a href=\"#s63\">14.1</a>)].</span> Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.</p></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s2a\"></a><a name=\"section-1.2\"></a><p></p><h2>1.2 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma</h2><p class=\"First\" style=\"border-left:1px solid;\"><span class=\"XmChange\"></span>JAYPIRCA is indicated for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.</p><p>This indication is approved under accelerated approval based on response rate <span class=\"Italics\">[see Clinical Studies (<a href=\"#s64\">14.2</a>)].</span> Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.</p></div></section>",
    "dosageAndAdministration": "<section class=\"Section\" data-sectioncode=\"34068-7\"><a name=\"s3\"></a><a name=\"section-2\"></a><p></p><h1>2 DOSAGE AND ADMINISTRATION</h1><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s4\"></a><a name=\"section-2.1\"></a><p></p><h2>2.1 Recommended Dosage</h2><p class=\"First\">The recommended dosage of JAYPIRCA is 200 mg orally once daily until disease progression or unacceptable toxicity.</p><p>Advise patients of the following:</p><ul class=\"Disc\"><li>Swallow tablets whole with water. Do not cut, crush, or chew tablets.</li><li>Take JAYPIRCA at the same time each day. JAYPIRCA may be taken with or without food.</li><li>If a dose of JAYPIRCA is missed by more than 12 hours, do not make up the dose and take the next dose as scheduled.</li></ul></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s5\"></a><a name=\"section-2.2\"></a><p></p><h2>2.2 Dosage Modifications for Adverse Reactions</h2><p class=\"First\">Recommended dosage modifications of JAYPIRCA for adverse reactions are presented in <a href=\"#t1\">Table 1</a><span class=\"Italics\">[see Warnings and Precautions (<a href=\"#s12\">5.1</a>, <a href=\"#s13\">5.2</a>, <a href=\"#s14\">5.3</a>, and <a href=\"#s15\">5.4</a>)]</span>.</p><a name=\"t1\"></a><table width=\"100%\"><caption><span>Table 1: Recommended Dosage Modification of JAYPIRCA for Adverse Reactions</span></caption><col align=\"left\" width=\"31.933%\"/><col align=\"left\" width=\"23.567%\"/><col align=\"left\" width=\"44.500%\"/><tfoot><tr class=\"First\"><td align=\"left\" colspan=\"3\" valign=\"top\"><p class=\"First Footnote\">Dose modification is not recommended for asymptomatic lymphocytosis. Asymptomatic lipase increase may not necessarily warrant dose modification.</p></td></tr><tr class=\"Last\"><td align=\"left\" colspan=\"3\" valign=\"top\"><p class=\"First Footnote\"><span class=\"Sup\">a</span> Evaluate the benefit-risk before resuming treatment at the same dose for a Grade 4 non-hematological toxicity.</p></td></tr></tfoot><tbody class=\"Headless\"><tr class=\"First\"><td align=\"left\" class=\"Botrule Lrule Rrule Toprule\" valign=\"top\"><span class=\"Bold\">Adverse Reaction</span></td><td align=\"left\" class=\"Botrule Rrule Toprule\" valign=\"top\"><span class=\"Bold\">Occurrences Requiring Dosage Modification</span></td><td align=\"left\" class=\"Botrule Rrule Toprule\" valign=\"top\"><span class=\"Bold\">Modification</span><br/>(Starting Dosage: 200 mg once daily)</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" rowspan=\"4\" valign=\"top\"><ul class=\"Disc\"><li>Grade 3 or greater non-hematologic toxicity <span class=\"Sup\">a</span></li><li>Absolute neutrophil count &lt; 1 to 0.5 x 10<span class=\"Sup\">9</span>/L with fever and/or infection</li><li>Absolute neutrophil count &lt; 0.5 x 10<span class=\"Sup\">9</span>/L lasting 7 or more days</li><li>Platelet count &lt; 50 to 25 x 10<span class=\"Sup\">9</span>/L with bleeding</li><li>Platelet count &lt; 25 x 10<span class=\"Sup\">9</span>/L</li></ul></td><td align=\"left\" class=\"Botrule Rrule\" valign=\"top\"><span class=\"Bold\">First occurrence</span></td><td align=\"left\" class=\"Botrule Rrule\" valign=\"top\">Interrupt JAYPIRCA until recovery to Grade 1 or baseline; restart at original dosage (200 mg once daily)<span class=\"Sup\">a</span>.</td></tr><tr><td align=\"left\" class=\"Botrule Rrule\" valign=\"top\"><span class=\"Bold\">Second occurrence</span></td><td align=\"left\" class=\"Botrule Rrule\" valign=\"top\">Interrupt JAYPIRCA until recovery to Grade 1 or baseline; restart at 100 mg once daily.</td></tr><tr><td align=\"left\" class=\"Botrule Rrule\" valign=\"top\"><span class=\"Bold\">Third occurrence</span></td><td align=\"left\" class=\"Botrule Rrule\" valign=\"top\">Interrupt JAYPIRCA until recovery to Grade 1 or baseline; restart at 50 mg once daily.</td></tr><tr class=\"Last\"><td align=\"left\" class=\"Botrule Rrule\" valign=\"top\"><span class=\"Bold\">Fourth occurrence</span></td><td align=\"left\" class=\"Botrule Rrule\" valign=\"top\">Discontinue JAYPIRCA.</td></tr></tbody></table></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s6\"></a><a name=\"section-2.3\"></a><p></p><h2>2.3 Dosage Modifications for Patients with Severe Renal Impairment</h2><p class=\"First\">For patients with severe renal impairment (eGFR 15-29 mL/min), reduce the JAYPIRCA dose to 100 mg once daily if the current dose is 200 mg once daily otherwise reduce the dose by 50 mg. If the current dosage is 50 mg once daily, discontinue JAYPIRCA <span class=\"Italics\">[see Use in Specific Populations (<a href=\"#s42\">8.7</a>), Clinical Pharmacology (<a href=\"#s48\">12.3</a>)]</span>. No dosage adjustment of JAYPIRCA is recommended in patients with mild to moderate renal impairment (eGFR 30-89 mL/min).</p></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s7\"></a><a name=\"section-2.4\"></a><p></p><h2>2.4 Dosage Modifications for Concomitant Use with Strong CYP3A Inhibitors</h2><p class=\"First\">Avoid concomitant use of strong CYP3A inhibitors with JAYPIRCA <span class=\"Italics\">[see Drug Interactions (<a href=\"#s23\">7.1</a>), Clinical Pharmacology (<a href=\"#s48\">12.3</a>)]</span>. If concomitant use of a strong CYP3A inhibitor is unavoidable, reduce the JAYPIRCA dose by 50 mg. If the current dosage is 50 mg once daily, interrupt JAYPIRCA treatment for the duration of strong CYP3A inhibitor use. After discontinuation of a strong CYP3A inhibitor for 5 half-lives, resume the JAYPIRCA dose that was taken prior to initiating the strong CYP3A inhibitor.</p></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s8\"></a><a name=\"section-2.5\"></a><p></p><h2>2.5 Dosage Modifications for Concomitant Use with CYP3A Inducers</h2><p class=\"First\">Avoid concomitant use of strong or moderate CYP3A inducers with JAYPIRCA <span class=\"Italics\">[see Drug Interactions (<a href=\"#s23\">7.1</a>), Clinical Pharmacology (<a href=\"#s48\">12.3</a>)]</span>. If concomitant use with moderate CYP3A inducers is unavoidable and the current dosage of JAYPIRCA is 200 mg once daily, increase the dose to 300 mg. If the current dosage is 50 mg or 100 mg once daily, increase the dose by 50 mg.</p></div></section>",
    "dosageFormsAndStrengths": "<section class=\"Section\" data-sectioncode=\"43678-2\"><a name=\"s9\"></a><a name=\"section-3\"></a><p></p><h1>3 DOSAGE FORMS AND STRENGTHS</h1><p class=\"First\">Tablets:</p><p>Each 50 mg tablet is blue, arc-triangle shaped, film-coated, and debossed with “Lilly 50” on one side and “6902” on the other side.</p><p>Each 100 mg tablet is blue, round, film-coated, and debossed with “Lilly 100” on one side and “7026” on the other side.</p></section>",
    "warningsAndPrecautions": "<section class=\"Section\" data-sectioncode=\"43685-7\"><a name=\"s11\"></a><a name=\"section-5\"></a><p></p><h1>5 WARNINGS AND PRECAUTIONS</h1><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s12\"></a><a name=\"section-5.1\"></a><p></p><h2>5.1 Infections</h2><p class=\"First\">Fatal and serious infections (including bacterial, viral, or fungal infections) and opportunistic infections have occurred in patients treated with JAYPIRCA. In the clinical trial, Grade 3 or higher infections occurred in 24% of 593 patients, most commonly pneumonia (14%), with fatal infections occurring in 4.4% of patients. Sepsis occurred in 6% of patients and febrile neutropenia in 4%. In patients with CLL/SLL, Grade 3 or higher infections occurred in 32% of patients, with fatal infections occurring in 8%. Opportunistic infections after treatment with JAYPIRCA have included, but are not limited to, <span class=\"Italics\">Pneumocystis jirovecii</span> pneumonia and fungal infection <span class=\"Italics\">[see Adverse Reactions (<a href=\"#s19\">6.1</a>)]</span>.</p><p>Consider prophylaxis, including vaccinations and antimicrobial prophylaxis, in patients who are at increased risk for infections, including opportunistic infections. Monitor patients for signs and symptoms of infection, evaluate promptly, and treat appropriately. Based on severity, reduce dose, temporarily withhold, or permanently discontinue JAYPIRCA <span class=\"Italics\">[see Dosage and Administration (<a href=\"#s5\">2.2</a>)]</span>.</p></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s13\"></a><a name=\"section-5.2\"></a><p></p><h2>5.2 Hemorrhage</h2><p class=\"First\">Fatal and serious hemorrhage has occurred with JAYPIRCA. Major hemorrhage (defined as Grade 3 or higher bleeding or any central nervous system bleeding) occurred in 3% of 593 patients treated with JAYPIRCA, including gastrointestinal hemorrhage; fatal hemorrhage occurred in 0.3% of patients. Bleeding of any grade, excluding bruising and petechiae, occurred in 17% of patients <span class=\"Italics\">[see Adverse Reactions (<a href=\"#s19\">6.1</a>)]</span>.</p><p>Major hemorrhage occurred in 2.3% of patients taking JAYPIRCA without antithrombotic agents and 0.7% of patients taking JAYPIRCA with antithrombotic agents. Consider the risks and benefits of antithrombotic agents when co-administered with JAYPIRCA. Monitor patients for signs of bleeding. Based on severity of bleeding, reduce dose, temporarily withhold, or permanently discontinue JAYPIRCA <span class=\"Italics\">[see Dosage and Administration (<a href=\"#s5\">2.2</a>)]</span>.</p><p>Consider the benefit-risk of withholding JAYPIRCA for 3 to 7 days pre- and post-surgery depending upon the type of surgery and risk of bleeding.</p></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s14\"></a><a name=\"section-5.3\"></a><p></p><h2>5.3 Cytopenias</h2><p class=\"First\">JAYPIRCA can cause cytopenias, including neutropenia, thrombocytopenia, and anemia.</p><p>In the clinical trial, Grade 3 or 4 cytopenias, including decreased neutrophils (26%), decreased platelets (12%), and decreased hemoglobin (12%) developed in patients treated with JAYPIRCA. Grade 4 decreased neutrophils developed in 14% of patients and Grade 4 decreased platelets developed in 6% of patients <span class=\"Italics\">[see Adverse Reactions (<a href=\"#s19\">6.1</a>)]</span>.</p><p>Monitor complete blood counts regularly during treatment. Based on severity, reduce dose, temporarily withhold, or permanently discontinue JAYPIRCA <span class=\"Italics\">[see Dosage and Administration (<a href=\"#s5\">2.2</a>)].</span></p></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s15\"></a><a name=\"section-5.4\"></a><p></p><h2>5.4 Cardiac Arrhythmias</h2><p class=\"First\">Cardiac arrhythmias, including atrial fibrillation and atrial flutter, were reported in recipients of JAYPIRCA. Atrial fibrillation or flutter were reported in 3.2% of patients, with Grade 3 or 4 atrial fibrillation or flutter reported in 1.5% of 593 patients in the clinical trial <span class=\"Italics\">[see Adverse Reactions (<a href=\"#s19\">6.1</a>)]</span>. Other serious cardiac arrhythmias such as supraventricular tachycardia and cardiac arrest occurred in 0.5% of patients. Patients with cardiac risk factors, such as hypertension, or previous arrhythmias may be at increased risk.</p><p>Monitor for signs and symptoms of arrhythmias (e.g., palpitations, dizziness, syncope, dyspnea) and manage appropriately. Based on severity, reduce dose, temporarily withhold, or permanently discontinue JAYPIRCA <span class=\"Italics\">[see Dosage and Administration (<a href=\"#s5\">2.2</a>)]</span>.</p></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s16\"></a><a name=\"section-5.5\"></a><p></p><h2>5.5 Second Primary Malignancies</h2><p class=\"First\">Second primary malignancies, including non-skin carcinomas, developed in 9% of 593 patients treated with JAYPIRCA monotherapy. The most frequent malignancy was non-melanoma skin cancer, reported in 4.6% of 593 patients. Other second primary malignancies included solid tumors (including genitourinary and breast cancers) and melanoma. Advise patients to use sun protection and monitor patients for the development of second primary malignancies.</p></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s16a\"></a><a name=\"section-5.6\"></a><p></p><h2 style=\"border-left:1px solid;\"><span class=\"XmChange\"></span>5.6 Hepatotoxicity, Including Drug-Induced Liver Injury</h2><p class=\"First\" style=\"border-left:1px solid;\"><span class=\"XmChange\"></span>Hepatotoxicity, including severe, life-threatening, and potentially fatal cases of drug-induced liver injury (DILI), has occurred in patients treated with Bruton tyrosine kinase inhibitors, including JAYPIRCA.</p><p style=\"border-left:1px solid;\"><span class=\"XmChange\"></span>Evaluate bilirubin and transaminases at baseline and throughout treatment with JAYPIRCA. For patients who develop abnormal liver tests after JAYPIRCA, monitor more frequently for liver test abnormalities and clinical signs and symptoms of hepatic toxicity. If DILI is suspected, withhold JAYPIRCA. Upon confirmation of DILI, discontinue JAYPIRCA.</p></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s17\"></a><a name=\"section-5.7\"></a><p></p><h2>5.7 Embryo-Fetal Toxicity</h2><p class=\"First\">Based on findings in animals, JAYPIRCA can cause fetal harm when administered to a pregnant woman. In animal reproduction studies, administration of pirtobrutinib to pregnant rats during the period of organogenesis caused embryo-fetal toxicity including embryo-fetal mortality and malformations at maternal exposures (AUC) approximately 3-times the recommended dose of 200 mg once daily. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with JAYPIRCA and for one week after the last dose <span class=\"Italics\">[see Use in Specific Populations (<a href=\"#s29\">8.1</a>, <a href=\"#s35\">8.3</a>)].</span></p></div></section>",
    "adverseReactions": "<section class=\"Section\" data-sectioncode=\"34084-4\"><a name=\"s18\"></a><a name=\"section-6\"></a><p></p><h1>6 ADVERSE REACTIONS</h1><p class=\"First\">The following clinically significant adverse reactions are described elsewhere in the labeling:</p><ul class=\"Disc\"><li>Infections <span class=\"Italics\">[see Warnings and Precautions (<a href=\"#s12\">5.1</a>)]</span></li><li>Hemorrhage <span class=\"Italics\">[see Warnings and Precautions (<a href=\"#s13\">5.2</a>)]</span></li><li>Cytopenias <span class=\"Italics\">[see Warnings and Precautions (<a href=\"#s14\">5.3</a>)]</span></li><li>Atrial Fibrillation and Atrial Flutter <span class=\"Italics\">[see Warnings and Precautions (<a href=\"#s15\">5.4</a>)]</span></li><li>Second Primary Malignancies <span class=\"Italics\">[see Warnings and Precautions (<a href=\"#s16\">5.5</a>)]</span></li><li>Hepatotoxicity, including DILI <span class=\"Italics\">[see Warnings and Precautions (<a href=\"#s16a\">5.6</a>)]</span></li></ul><div class=\"Section\" data-sectioncode=\"90374-0\"><a name=\"s19\"></a><a name=\"section-6.1\"></a><p></p><h2>6.1 Clinical Trials Experience</h2><p class=\"First\">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be compared to rates in the clinical trials of another drug and may not reflect the rates observed in the general patient population.</p><p>The data in the WARNINGS AND PRECAUTIONS reflect exposure to JAYPIRCA as a single-agent, administered at 200 mg once daily in 593 patients with hematologic malignancies in the BRUIN study. Among these 593 patients, the median duration of exposure was 10 months, 62% were exposed for at least 6 months and 45% were exposed for at least one year.</p><p>In this pooled safety population, the most common (≥ 20%) adverse reactions, including laboratory abnormalities, were decreased neutrophil count (46%), decreased hemoglobin (39%), fatigue (32%), decreased lymphocyte count (31%), musculoskeletal pain (30%), decreased platelet count (29%), diarrhea (24%), COVID-19 (22%), bruising (21%), and cough (20%).</p><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s19a\"></a><a name=\"section-6.1.1\"></a><p></p><p class=\"First\"><span class=\"Underline\">Mantle Cell Lymphoma</span></p><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s19b\"></a><a name=\"section-6.1.1.1\"></a><p></p><p class=\"First\"><span class=\"Italics\">BRUIN</span></p><p>The safety of JAYPIRCA was evaluated in the BRUIN trial in patients with MCL who received a prior BTK inhibitor <span class=\"Italics\">[see Clinical Studies (<a href=\"#s63\">14.1</a></span>)<span class=\"Italics\">]</span>. The trial required a platelet count ≥ 50 x 10<span class=\"Sup\">9</span>/L, absolute neutrophil count ≥ 0.75 x 10<span class=\"Sup\">9</span>/L, hepatic transaminases ≤ 2.5 times upper limit of normal (ULN), and an ECOG performance status of 0 to 2. The trial excluded patients with active central nervous system (CNS) involvement by lymphoma, significant cardiovascular disease, major bleeding or grade ≥ 3 arrhythmia with a prior BTK inhibitor, prolonged QTc interval, or need for a strong CYP3A inhibitor or inducer or strong P-gp inhibitor.</p><p>Patients received JAYPIRCA 200 mg orally once daily until disease progression or unacceptable toxicity (n = 128); 36% were exposed for 6 months or longer and 10% were exposed for at least one year. The median number of prior therapies was 3 (range: 1-9). The median age was 71 years (range: 46 to 88 years) and 80% of patients were male. Race was reported for all patients; 78% were White, 14% were Asian, 2.3% were Black, and 2.3% were Hispanic or Latino.</p><p>Serious adverse reactions occurred in 38% of patients who received JAYPIRCA. Serious adverse reactions that occurred in ≥ 2% of patients were pneumonia (14%), COVID-19 (4.7%), musculoskeletal pain (3.9%), hemorrhage (2.3%), pleural effusion (2.3%), and sepsis (2.3%). Fatal adverse reactions within 28 days of the last dose of JAYPIRCA occurred in 7% of patients, most commonly due to infections (4.7%) including COVID-19 (3.1% of all patients).</p><p>Adverse reactions led to dose reductions in 4.7%, treatment interruption in 32%, and permanent discontinuation of JAYPIRCA in 9%. Adverse reactions that resulted in dosage modification in &gt; 5% of patients included pneumonia and neutropenia. Adverse reactions which resulted in permanent discontinuation of JAYPIRCA in &gt; 1% of patients included pneumonia.</p><p>The most common adverse reactions (≥ 15%), excluding laboratory terms, were fatigue, musculoskeletal pain, diarrhea, edema, dyspnea, pneumonia, and bruising.</p><p><a href=\"#t2\">Table 2</a> summarizes select adverse reactions in BRUIN.</p><a name=\"t2\"></a><table width=\"100%\"><caption><span>Table 2: Adverse Reactions (≥ 10%) in Patients with MCL Who Received JAYPIRCA</span></caption><col align=\"left\" width=\"37.467%\"/><col align=\"left\" width=\"31.267%\"/><col align=\"left\" width=\"31.267%\"/><thead><tr class=\"First\"><th align=\"left\" class=\"Botrule Lrule Rrule Toprule\" rowspan=\"2\" valign=\"top\"></th><th align=\"center\" class=\"Botrule Rrule Toprule\" colspan=\"2\" valign=\"top\"><span class=\"Bold\">JAYPIRCA</span><br/><span class=\"Bold\">200 mg once daily</span></th></tr><tr class=\"Last\"><th align=\"center\" class=\"Botrule Rrule\" colspan=\"2\" valign=\"bottom\"><span class=\"Bold\">N = 128</span></th></tr></thead><tfoot><tr class=\"First\"><td align=\"left\" colspan=\"3\" valign=\"top\"><p class=\"First Footnote\"><span class=\"Sup\">a</span> Each term listed includes other related terms.</p></td></tr><tr><td align=\"left\" colspan=\"3\" valign=\"top\"><p class=\"First Footnote\"><span class=\"Sup\">b</span> includes 1 fatality from COVID-19 pneumonia</p></td></tr><tr class=\"Last\"><td align=\"left\" colspan=\"3\" valign=\"top\"><p class=\"First Footnote\"><span class=\"Sup\">c</span> includes 1 fatality from hemorrhage</p></td></tr></tfoot><tbody><tr class=\"First\"><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"bottom\"><span class=\"Bold\">Adverse Reactions</span><span class=\"Bold\"><span class=\"Sup\">a</span></span></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"bottom\"><span class=\"Bold\">All Grades (%)</span></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"bottom\"><span class=\"Bold\">Grade 3-4 (%)</span></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" colspan=\"3\" valign=\"top\"><span class=\"Bold\">General Disorders</span></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Fatigue</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">29</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">1.6</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Edema</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">18</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">0.8</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Fever</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">13</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" colspan=\"3\" valign=\"top\"><span class=\"Bold\">Musculoskeletal and Connective Tissue Disorders</span></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Musculoskeletal pain</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">27</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">3.9</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Arthritis or arthralgia</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">12</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">0.8</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" colspan=\"3\" valign=\"top\"><span class=\"Bold\">Gastrointestinal Disorders</span></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Diarrhea</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">19</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Constipation</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">13</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Abdominal pain</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">11</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">0.8</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Nausea</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">11</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" colspan=\"3\" valign=\"top\"><span class=\"Bold\">Respiratory, thoracic, and mediastinal disorders</span></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Dyspnea</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">17</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">2.3</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Cough</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">14</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" colspan=\"3\" valign=\"top\"><span class=\"Bold\">Injury</span></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Bruising</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">16</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" colspan=\"3\" valign=\"top\"><span class=\"Bold\">Infections</span></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Pneumonia</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">16 <span class=\"Sup\">b</span></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">14</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Upper respiratory tract infections</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">10</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">0.8</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" colspan=\"3\" valign=\"top\"><span class=\"Bold\">Nervous system disorders</span></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Peripheral neuropathy</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">14</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">0.8</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Dizziness</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">10</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" colspan=\"3\" valign=\"top\"><span class=\"Bold\">Skin and subcutaneous disorders</span></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Rash</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">14</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" colspan=\"3\" valign=\"top\"><span class=\"Bold\">Vascular disorders</span></td></tr><tr class=\"Last\"><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Hemorrhage</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">11 <span class=\"Sup\">c</span></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">3.1</td></tr></tbody></table><p>Clinically relevant adverse reactions in &lt; 10% include vision changes, memory changes, headache, urinary tract infection, herpesvirus infection, and tumor lysis syndrome.</p><p><a href=\"#t3\">Table 3</a> summarizes laboratory abnormalities in BRUIN.</p><a name=\"t3\"></a><table width=\"100%\"><caption><span>Table 3: Select Laboratory Abnormalities (≥ 10%) That Worsened from Baseline in Patients with MCL Who Received JAYPIRCA</span></caption><col align=\"left\" width=\"37.467%\"/><col align=\"left\" width=\"31.267%\"/><col align=\"left\" width=\"31.267%\"/><tfoot><tr class=\"First Last\"><td align=\"left\" colspan=\"3\" valign=\"top\"><p class=\"First Footnote\"><span class=\"Sup\">a</span>  The denominator used to calculate the rate varied from 90 to 127 based on the number of patients with a baseline value and at least one post-treatment value.</p></td></tr></tfoot><tbody class=\"Headless\"><tr class=\"First\"><td align=\"left\" class=\"Botrule Lrule Rrule Toprule\" rowspan=\"2\" valign=\"top\"><span class=\"Bold\">Laboratory Abnormality</span></td><td align=\"center\" class=\"Botrule Rrule Toprule\" colspan=\"2\" valign=\"top\"><span class=\"Bold\">JAYPIRCA</span><span class=\"Bold\"><span class=\"Sup\">a</span></span><br/><span class=\"Bold\">200 mg once daily</span></td></tr><tr><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"><span class=\"Bold\">All Grades (%)</span></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"><span class=\"Bold\">Grade 3 or 4 (%)</span></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\"><span class=\"Bold\">Hematology</span></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Hemoglobin decreased</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">42</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">9</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Platelet count decreased</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">39</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">14</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Neutrophil count decreased</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">36</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">16</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Lymphocyte count decreased</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">32</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">15</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\"><span class=\"Bold\">Chemistry</span></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Creatinine increased</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">30</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">1.6</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Calcium decreased</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">19</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">1.6</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">AST increased</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">17</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">1.6</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Potassium decreased</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">13</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">1.6</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Sodium decreased</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">13</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Lipase increased</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">12</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">4.4</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Alkaline phosphatase increased</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">11</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">ALT increased</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">11</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">1.6</td></tr><tr class=\"Last\"><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Potassium increased</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">11</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">0.8</td></tr></tbody></table><p>Grade 4 laboratory abnormalities in &gt; 5% of patients included neutrophils decreased (10%), platelets decreased (7%), and lymphocytes decreased (6%).</p><p><span class=\"Underline\">Lymphocytosis</span>: Upon initiation of JAYPIRCA, a temporary increase in lymphocyte counts (defined as absolute lymphocyte count increased ≥ 50% from baseline and a post-baseline value ≥ 5,000/μL) occurred in 34% of MCL patients in BRUIN. The median time to onset of lymphocytosis was 1.1 weeks, with 75% of cases occurring within 2.1 weeks, and the median duration was 11 weeks.</p></div></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s20\"></a><a name=\"section-6.1.2\"></a><p></p><p class=\"First\"><span class=\"Underline\">Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma</span></p><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s20a\"></a><a name=\"section-6.1.2.1\"></a><p></p><p class=\"First\"><span class=\"Italics\">BRUIN</span></p><p>The safety of JAYPIRCA was evaluated in the BRUIN trial in 110 patients with CLL/SLL, with 98% receiving at least two prior lines of systemic therapy including a BTK inhibitor and a BCL-2 inhibitor <span class=\"Italics\">[see Clinical Studies (<a href=\"#s64\">14.2</a></span>)<span class=\"Italics\">]</span>. The trial required a platelet count ≥ 50 x 10<span class=\"Sup\">9</span>/L, absolute neutrophil count ≥ 0.75 x 10<span class=\"Sup\">9</span>/L, hepatic transaminases ≤ 2.5 times upper limit of normal (ULN), and an ECOG performance status of 0 to 2. The trial excluded patients with active central nervous system (CNS) involvement by lymphoma, significant cardiovascular disease, major bleeding, uncontrolled or symptomatic arrhythmias, prolonged QTc interval, or need for a strong CYP3A inhibitor or inducer or strong P-gp inhibitor.</p><p>Patients received JAYPIRCA 200 mg orally once daily until disease progression or unacceptable toxicity (N = 110); 60% were exposed for at least 1 year and 14% were exposed for at least two years. The median age was 68 years (range: 41 to 88 years) and 67% of patients were male. Race was reported in 110 (100%) patients; of these patients, 89% were White, 4.5% were Black, 1.8% were Asian, and 1.8% were Hispanic or Latino. The median number of prior therapies was 5 (range: 1-11).</p><p>Serious adverse reactions occurred in 56% of patients who received JAYPIRCA. Serious adverse reactions that occurred in ≥ 5% of patients were pneumonia (18%), COVID-19 (9%), sepsis (7%), and febrile neutropenia (7%). Fatal adverse reactions within 28 days of the last dose of JAYPIRCA occurred in 11% of patients, most commonly due to infections (10%), including sepsis (5%) and COVID-19 (2.7%).</p><p>Adverse reactions led to dose reductions in 3.6%, treatment interruption in 42%, and permanent discontinuation of JAYPIRCA in 9%. Adverse reactions which resulted in dose reductions of JAYPIRCA in &gt; 1% of patients included neutropenia. Adverse reactions which resulted in treatment interruptions of JAYPIRCA in &gt; 5% of patients included pneumonia, neutropenia, febrile neutropenia, and COVID-19. Adverse reactions which resulted in permanent discontinuation of JAYPIRCA in &gt; 1% of patients included second primary malignancy, COVID-19, and sepsis.</p><p>The most common adverse reactions (≥ 20%), excluding laboratory terms, were fatigue, bruising, cough, musculoskeletal pain, COVID-19, diarrhea, pneumonia, abdominal pain, dyspnea, hemorrhage, edema, nausea, pyrexia, and headache. <a href=\"#t4\">Table 4</a> summarizes select adverse reactions for patients treated on BRUIN.</p><a name=\"t4\"></a><table width=\"100%\"><caption><span>Table 4: Adverse Reactions (≥ 10%) in Patients with CLL/SLL Who Received JAYPIRCA</span></caption><col align=\"left\" width=\"37.467%\"/><col align=\"left\" width=\"31.267%\"/><col align=\"left\" width=\"31.267%\"/><thead><tr class=\"First\"><th align=\"left\" class=\"Botrule Lrule Rrule Toprule\" rowspan=\"2\" valign=\"top\"></th><th align=\"center\" class=\"Botrule Rrule Toprule\" colspan=\"2\" valign=\"top\"><span class=\"Bold\">JAYPIRCA</span><br/><span class=\"Bold\">200 mg once daily</span></th></tr><tr><th align=\"center\" class=\"Botrule Rrule\" colspan=\"2\" valign=\"bottom\"><span class=\"Bold\">N = 110</span></th></tr><tr class=\"Last\"><th align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"bottom\"><span class=\"Bold\">Adverse Reactions</span><span class=\"Bold\"><span class=\"Sup\">a</span></span></th><th align=\"center\" class=\"Botrule Rrule\" valign=\"bottom\"><span class=\"Bold\">All Grades (%)</span></th><th align=\"center\" class=\"Botrule Rrule\" valign=\"bottom\"><span class=\"Bold\">Grade 3-4 (%)</span></th></tr></thead><tfoot><tr class=\"First\"><td align=\"left\" colspan=\"3\" valign=\"top\"><p class=\"First Footnote\"><span class=\"Sup\">a</span> Each term listed includes other related terms.</p></td></tr><tr><td align=\"left\" colspan=\"3\" valign=\"top\"><p class=\"First Footnote\"><span class=\"Sup\">b</span> Includes COVID-19 pneumonia. Includes 1 fatalities from COVID-19 and 2 fatalities from COVID-19 pneumonia</p></td></tr><tr><td align=\"left\" colspan=\"3\" valign=\"top\"><p class=\"First Footnote\"><span class=\"Sup\">c</span> Includes COVID-19 pneumonia. Includes 2 fatalities from COVID-19 pneumonia and 1 fatality from pneumonia</p></td></tr><tr><td align=\"left\" colspan=\"3\" valign=\"top\"><p class=\"First Footnote\"><span class=\"Sup\">d</span> Includes preferred terms hemorrhage, intracranial hemorrhage, and gastrointestinal hemorrhage</p></td></tr><tr><td align=\"left\" colspan=\"3\" valign=\"top\"><p class=\"First Footnote\"><span class=\"Sup\">e</span> Includes preferred terms memory impairment, confusional state, encephalopathy, mental status changes</p></td></tr><tr><td align=\"left\" colspan=\"3\" valign=\"top\"><p class=\"First Footnote\"><span class=\"Sup\">f</span> Includes preferred terms second primary malignancy and nonmelanoma skin cancers. 1 fatality from metastatic malignant melanoma</p></td></tr><tr><td align=\"left\" colspan=\"3\" valign=\"top\"><p class=\"First Footnote\"><span class=\"Sup\">g</span> Includes preferred terms renal failure, chronic kidney disease, acute kidney injury</p></td></tr><tr class=\"Last\"><td align=\"left\" colspan=\"3\" valign=\"top\"><p class=\"First Footnote\"><span class=\"Sup\">h</span>Includes preferred terms supraventricular tachycardia, sinus tachycardia, atrial fibrillation</p></td></tr></tfoot><tbody><tr class=\"First\"><td align=\"left\" class=\"Botrule Lrule Rrule\" colspan=\"3\" valign=\"top\"><span class=\"Bold\">General Disorders</span></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Fatigue</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">36</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">2.7</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Edema</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">21</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">0</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Pyrexia</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">20</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">2.7</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" colspan=\"3\" valign=\"top\"><span class=\"Bold\">Injury</span></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Bruising</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">36</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">0</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Fall</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">14</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">0.9</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" colspan=\"3\" valign=\"top\"><span class=\"Bold\">Respiratory, thoracic, and mediastinal disorders</span></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Cough</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">33</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">0</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Dyspnea</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">22</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">2.7</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Mucositis</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">12</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">0.9</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" colspan=\"3\" valign=\"top\"><span class=\"Bold\">Musculoskeletal and Connective Tissue Disorders</span></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Musculoskeletal pain</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">32</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">0.9</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Arthritis or arthralgia</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">19</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">1.8</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" colspan=\"3\" valign=\"top\"><span class=\"Bold\">Infections</span></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">COVID-19</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">28<span class=\"Sup\">b</span></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">7</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Pneumonia</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">27<span class=\"Sup\">c</span></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">16</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Upper respiratory tract infections</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">13</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">2.7</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Respiratory tract infection</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">11</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">1.8</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" colspan=\"3\" valign=\"top\"><span class=\"Bold\">Gastrointestinal Disorders</span></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Diarrhea</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">26</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">0</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Abdominal pain</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">25</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">2.7</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Nausea</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">21</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">0</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Constipation</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">14</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">0</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" colspan=\"3\" valign=\"top\"><span class=\"Bold\">Vascular disorders</span></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Hemorrhage</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">22<span class=\"Sup\">d</span></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">2.7</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Hypertension</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">12</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">5</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" colspan=\"3\" valign=\"top\"><span class=\"Bold\">Nervous system disorders</span></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Headache</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">20</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">0.9</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Peripheral neuropathy</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">16</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">3.6</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Dizziness</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">15</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">0</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Neurological changes</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">12<span class=\"Sup\">e</span></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">2.7</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\"><span class=\"Bold\">Skin and subcutaneous disorders</span></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Rash</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">19</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">0.9</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" colspan=\"3\" valign=\"top\"><span class=\"Bold\">Psychiatric disorders</span></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Insomnia</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">14</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">0</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" colspan=\"3\" valign=\"top\"><span class=\"Bold\">Neoplasms benign, malignant and unspecified</span></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Second primary malignancy</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">13<span class=\"Sup\">f</span></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">2.7</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" colspan=\"3\" valign=\"top\"><span class=\"Bold\">Renal and urinary disorders</span></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Renal insufficiency</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">12<span class=\"Sup\">g</span></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">6</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" colspan=\"3\" valign=\"top\"><span class=\"Bold\">Metabolism and nutrition disorders</span></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Decreased appetite</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">12</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">0</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" colspan=\"3\" valign=\"top\"><span class=\"Bold\">Cardiac disorders</span></td></tr><tr class=\"Last\"><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Supraventricular tachycardia</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">10<span class=\"Sup\">h</span></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">5</td></tr></tbody></table><p>Clinically relevant adverse reactions in &lt; 10% include vision changes, lower respiratory tract infection, urinary tract infection, herpesvirus infection, and tumor lysis syndrome.</p><p><a href=\"#t5\">Table 5</a> summarizes laboratory abnormalities in BRUIN.</p><a name=\"t5\"></a><table width=\"100%\"><caption><span>Table 5: Select Laboratory Abnormalities (≥ 20%) That Worsened from Baseline in Patients with CLL/SLL Who Received JAYPIRCA</span></caption><col align=\"left\" width=\"37.433%\"/><col align=\"left\" width=\"31.200%\"/><col align=\"left\" width=\"31.367%\"/><thead><tr class=\"First\"><th align=\"left\" class=\"Botrule Lrule Rrule Toprule\" rowspan=\"2\" valign=\"bottom\"><span class=\"Bold\">Laboratory Abnormality</span></th><th align=\"center\" class=\"Botrule Rrule Toprule\" colspan=\"2\" valign=\"bottom\"><span class=\"Bold\">JAYPIRCA</span><span class=\"Bold\"><span class=\"Sup\">a</span></span><br/><span class=\"Bold\">200 mg once daily<br/></span></th></tr><tr class=\"Last\"><th align=\"center\" class=\"Botrule Rrule\" valign=\"bottom\"><span class=\"Bold\">All Grades (%)</span></th><th align=\"center\" class=\"Botrule Rrule\" valign=\"bottom\"><span class=\"Bold\">Grade 3 or 4 (%)</span></th></tr></thead><tfoot><tr class=\"First Last\"><td align=\"left\" colspan=\"3\" valign=\"top\"><p class=\"First Footnote\"><span class=\"Sup\">a</span>  The denominator used to calculate the rate varied from 83 to 108 based on the number of patients with a baseline value and at least one post-treatment value.</p></td></tr></tfoot><tbody><tr class=\"First\"><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\"><span class=\"Bold\">Hematology</span></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Neutrophil count decreased</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">63</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">45</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Hemoglobin decreased</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">48</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">19</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Platelet count decreased</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">30</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">15</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Lymphocyte count decreased</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">23</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">8</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\"><span class=\"Bold\">Chemistry</span></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Calcium decreased</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">40</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">2.8</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Sodium decreased</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">30</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">0</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">ALT increased</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">23</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">2.8</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">AST increased</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">23</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">1.9</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Creatinine increased</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">23</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">0</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Lipase increased</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">21</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">7</td></tr><tr class=\"Last\"><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Alkaline phosphatase increased</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">21</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">0</td></tr></tbody></table><p>Grade 4 laboratory abnormalities in &gt; 5% of patients included neutrophils decreased (23%).</p></div></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s21\"></a><a name=\"section-6.1.3\"></a><p></p><p class=\"First\"><span class=\"Underline\">**Lymphocytosis</span>: Upon initiation of JAYPIRCA, a temporary increase in lymphocyte counts (defined as absolute lymphocyte count increased ≥ 50% from baseline and a post-baseline value ≥ 5,000/μL) occurred in 64% of CLL/SLL patients in BRUIN. The median time to onset of lymphocytosis was 1.1 weeks, with 75% of cases occurring within 1.1 weeks, and the median duration was 19 weeks.</p></div></div></section>",
    "drugInteractions": "<section class=\"Section\" data-sectioncode=\"34073-7\"><a name=\"s22\"></a><a name=\"section-7\"></a><p></p><h1>7 DRUG INTERACTIONS</h1><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s23\"></a><a name=\"section-7.1\"></a><p></p><h2>7.1 Effect of Other Drugs on JAYPIRCA</h2><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s24\"></a><a name=\"section-7.1.1\"></a><p></p><p class=\"First\"><span class=\"Underline\">Strong CYP3A Inhibitors</span></p><p>Pirtobrutinib is a CYP3A substrate. Concomitant use of JAYPIRCA with a strong CYP3A inhibitor increased pirtobrutinib systemic exposure <span class=\"Italics\">[see Clinical Pharmacology (<a href=\"#s48\">12.3</a>)]</span>, which may increase the risk of JAYPIRCA adverse reactions. Avoid concomitant use of strong CYP3A inhibitors during treatment with JAYPIRCA. If concomitant use of strong CYP3A inhibitors is unavoidable, reduce the JAYPIRCA dosage <span class=\"Italics\">[see Dosage and Administration (<a href=\"#s7\">2.4</a>)]</span>.</p></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s25\"></a><a name=\"section-7.1.2\"></a><p></p><p class=\"First\"><span class=\"Underline\">Strong or Moderate CYP3A Inducers</span></p><p>Concomitant use of JAYPIRCA with a strong or moderate CYP3A inducer decreased pirtobrutinib systemic exposure <span class=\"Italics\">[see Clinical Pharmacology (<a href=\"#s48\">12.3</a>)]</span>, which may reduce JAYPIRCA efficacy. Avoid concomitant use of JAYPIRCA with strong or moderate CYP3A inducers. If concomitant use of moderate CYP3A inducers is unavoidable, increase the JAYPIRCA dosage <span class=\"Italics\">[see Dosage and Administration (<a href=\"#s8\">2.5</a>)]</span>.</p></div></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s26\"></a><a name=\"section-7.2\"></a><p></p><h2>7.2 Effect of JAYPIRCA on Other Drugs</h2><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s27\"></a><a name=\"section-7.2.1\"></a><p></p><p class=\"First\"><span class=\"Underline\">Sensitive CYP2C8, CYP2C19, CYP3A, P-gp, or BCRP Substrates</span></p><p>JAYPIRCA is a P-gp inhibitor, a moderate CYP2C8 and BCRP inhibitor, and a weak CYP2C19 and CYP3A inhibitor. Concomitant use of JAYPIRCA with sensitive P-gp, CYP2C8, BCRP, CYP2C19, or CYP3A substrates increased their plasma concentrations <span class=\"Italics\">[see Clinical Pharmacology (<a href=\"#s48\">12.3</a>)],</span> which may increase the risk of adverse reactions related to these substrates for drugs which are sensitive to minimal concentration changes. Follow recommendations for sensitive CYP2C8, CYP2C19, CYP3A, P-gp, or BCRP substrates provided in their approved product labeling.</p></div></div></section>",
    "clinicalPharmacology": "<section class=\"Section\" data-sectioncode=\"34090-1\"><a name=\"s44\"></a><a name=\"section-10\"></a><p></p><h1>12 CLINICAL PHARMACOLOGY</h1><div class=\"Section\" data-sectioncode=\"43679-0\"><a name=\"s45\"></a><a name=\"section-10.1\"></a><p></p><h2>12.1 Mechanism of action</h2><p class=\"First\">Pirtobrutinib is a small molecule, noncovalent inhibitor of BTK. BTK is a signaling protein of the B-cell antigen receptor (BCR) and cytokine receptor pathways. In B-cells, BTK signaling results in activation of pathways necessary for B-cell proliferation, trafficking, chemotaxis, and adhesion. Pirtobrutinib binds to wild type BTK and BTK harboring C481 mutations, leading to inhibition of BTK kinase activity. In nonclinical studies, pirtobrutinib inhibited BTK-mediated B-cell CD69 expression and inhibited malignant B-cell proliferation. Pirtobrutinib showed dose-dependent anti-tumor activities in BTK wild type and BTK C481S mutant mouse xenograft models.</p></div><div class=\"Section\" data-sectioncode=\"43681-6\"><a name=\"s46\"></a><a name=\"section-10.2\"></a><p></p><h2>12.2 Pharmacodynamics</h2><p class=\"First\">At the recommended dosage of 200 mg once daily, pirtobrutinib trough concentrations exceeded the BTK IC<span class=\"Sub\">96</span>. BTK occupancy is maintained throughout the dosing interval, regardless of the intrinsic rate of BTK turnover.</p><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s47\"></a><a name=\"section-10.2.1\"></a><p></p><p class=\"First\"><span class=\"Underline\">Cardiac Electrophysiology</span></p><p>The effect of a single 900 mg dose of pirtobrutinib (equivalent to approximately 2 times higher than the concentrations achieved at steady state at the recommended dosage of 200 mg once daily) on the QTc interval was evaluated in a placebo-controlled and positive-controlled study in 30 healthy subjects. Pirtobrutinib had no clinically meaningful effect on the change in QTcF interval (i.e., &gt; 10 ms) and there was no relationship between pirtobrutinib exposure and change in QTc interval.</p></div></div><div class=\"Section\" data-sectioncode=\"43682-4\"><a name=\"s48\"></a><a name=\"section-10.3\"></a><p></p><h2>12.3 Pharmacokinetics</h2><p class=\"First\">The pharmacokinetics of pirtobrutinib were characterized in healthy subjects and in patients with cancer. Pirtobrutinib exposure (AUC) and C<span class=\"Sub\">max</span> increases proportionally following single oral doses ranging from 300 mg to 800 mg (1.5 to 4 times the approved recommended dosage) and once daily doses ranging from 25 – 300 mg (0.125 to 1.5 times the recommended dosage). Steady state was achieved within 5 days of once daily dosing, and the mean (CV%) accumulation ratio was 1.63 (26.7%) based on AUC after administration of 200 mg dosages.</p><p>Following administration of the recommended dosage, the geometric mean (CV%) steady-state AUC and C<span class=\"Sub\">max</span> of pirtobrutinib were 90300 h*ng/mL (40%) and 6380 ng/mL (26%), respectively. The geometric mean (CV%) AUC<span class=\"Sub\">0-24</span> and C<span class=\"Sub\">max</span> of pirtobrutinib on Cycle 1 Day 8 were 81800 h*ng/mL (66.6%) and 3670 ng/mL (89.5%), respectively.</p><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s49\"></a><a name=\"section-10.3.1\"></a><p></p><p class=\"First\"><span class=\"Underline\">Absorption</span></p><p>The absolute bioavailability of pirtobrutinib after a single oral 200 mg dose is 85.5% (range 75.9% to 90.9%). The median time (range) to reach peak plasma concentration (t<span class=\"Sub\">max</span>) is approximately 2 hours (0.833 to 4.15 hours).</p><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s50\"></a><a name=\"section-10.3.1.1\"></a><p></p><p class=\"First\"><span class=\"Italics\">Effect of Food</span></p><p>No clinically significant differences in the pharmacokinetics of pirtobrutinib were observed following administration of a high-fat, high-calorie meal (approximately 800 to 1000 calories with 150 calories from protein, 250 calories from carbohydrate, and 500 to 600 calories from fat) to healthy subjects. A high-fat meal decreased the C<span class=\"Sub\">max</span> of pirtobrutinib by 23% and delayed t<span class=\"Sub\">max</span> by 1 hour. There was no effect on pirtobrutinib AUC.</p></div></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s51\"></a><a name=\"section-10.3.2\"></a><p></p><p class=\"First\"><span class=\"Underline\">Distribution</span></p><p>The mean apparent central volume of distribution of pirtobrutinib is 34.1 L. Human protein binding of pirtobrutinib is 96% and is independent of concentration in vitro. Mean blood-to-plasma ratio is 0.79.</p></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s52\"></a><a name=\"section-10.3.3\"></a><p></p><p class=\"First\"><span class=\"Underline\">Elimination</span></p><p>The effective half-life of pirtobrutinib is approximately 19 hours and the mean (CV%) apparent clearance is 2.05 L/h (37.2%).</p><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s53\"></a><a name=\"section-10.3.3.1\"></a><p></p><p class=\"First\"><span class=\"Italics\">Metabolism</span></p><p>Pirtobrutinib is primarily metabolized by CYP3A4 and direct glucuronidation by UGT1A8 and UGT1A9, in vitro.</p></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s54\"></a><a name=\"section-10.3.3.2\"></a><p></p><p class=\"First\"><span class=\"Italics\">Excretion</span></p><p>Following a single radiolabeled dose of pirtobrutinib 200 mg to healthy subjects, 37% of the dose was recovered in feces (18% unchanged) and 57% in urine (10% unchanged).</p></div></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s55\"></a><a name=\"section-10.3.4\"></a><p></p><p class=\"First\"><span class=\"Underline\">Specific Populations</span></p><p>There were no clinically significant differences in the pharmacokinetics of pirtobrutinib based on age (range 22 – 95 years), sex, race/ethnicity (White 84%, Asian 7%), body weight (range 35.7 – 152 kg), mild (total bilirubin ≤ upper limit of normal (ULN) and aspartate aminotransferase (AST) &gt; ULN or total bilirubin &gt; 1 to 1.5 × ULN and any AST), moderate (total bilirubin &gt; 1.5 to 3 × ULN and any AST), or severe (total bilirubin &gt; 3 × ULN and any AST) hepatic impairment. The effect of other races/ethnicities on the pharmacokinetics of pirtobrutinib is unknown.</p><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s56\"></a><a name=\"section-10.3.4.1\"></a><p></p><p class=\"First\"><span class=\"Italics\">Patients with Renal Impairment</span></p><p>Following a single 200 mg oral dose, the AUC of pirtobrutinib in subjects with severe renal impairment (eGFR 15-29 mL/min) increased by 62% and mean unbound AUC increased by 68% compared to healthy subjects with normal renal function. There were no clinically significant differences in the pharmacokinetics of pirtobrutinib in subjects with mild (eGFR 60-89 mL/min) or moderate renal impairment (eGFR 30-59 mL/min). The effect of renal impairment requiring dialysis on the pharmacokinetics of pirtobrutinib is unknown.</p></div></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s57\"></a><a name=\"section-10.3.5\"></a><p></p><p class=\"First\"><span class=\"Underline\">Drug Interaction Studies</span></p><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s58\"></a><a name=\"section-10.3.5.1\"></a><p></p><p class=\"First\"><span class=\"Italics\">Clinical Studies and Model-Informed Approaches</span></p><p><span class=\"Italics\">Strong CYP3A Inhibitors:</span> Co-administration of a single 200 mg dose of pirtobrutinib with itraconazole (strong CYP3A inhibitor) increased AUC of pirtobrutinib by 49%.</p><p><span class=\"Italics\">Moderate CYP3A Inhibitors:</span> Verapamil and diltiazem (moderate CYP3A inhibitors) are predicted to increase the AUC of pirtobrutinib by 30% and 20%, respectively.</p><p><span class=\"Italics\">Strong CYP3A inducers:</span> Coadministration of a single 200 mg dose of pirtobrutinib with rifampin (strong CYP3A inducer) decreased the AUC of pirtobrutinib by 71%.</p><p><span class=\"Italics\">Moderate CYP3A Inducers:</span> Efavirenz and bosentan (moderate CYP3A inducers) are predicted to decrease the AUC of pirtobrutinib by 49% and 27%, respectively.</p><p><span class=\"Italics\">Gastric Reducing Agents:</span> No clinically significant differences in pirtobrutinib pharmacokinetics were observed when co-administered with omeprazole (a proton pump inhibitor).</p><p><span class=\"Italics\">P-glycoprotein (P-gp) inhibitors:</span> No clinically significant differences in pirtobrutinib pharmacokinetics were observed when co-administered with itraconazole (P-gp inhibitor).</p><p><span class=\"Italics\">CYP3A Substrates:</span> Pirtobrutinib increased the AUC and C<span class=\"Sub\">max</span> of orally administered midazolam (sensitive CYP3A substrate) by 70% and 58%, respectively. Pirtobrutinib did not have a clinically meaningful effect on the exposure of intravenously administered midazolam.</p><p><span class=\"Italics\">CYP2C8 Substrates:</span> Pirtobrutinib increased the AUC and C<span class=\"Sub\">max</span> of repaglinide (sensitive CYP2C8 substrate) by 130% and 98%, respectively.</p><p><span class=\"Italics\">CYP2C19 Substrates:</span> Pirtobrutinib increased the AUC and C<span class=\"Sub\">max</span> of omeprazole (sensitive CYP2C19 substrate) by 56% and 49%, respectively.</p><p><span class=\"Italics\">P-gp Substrates:</span> A single 200 mg dose of pirtobrutinib increased the AUC and C<span class=\"Sub\">max</span> of digoxin (sensitive P-gp substrate) by 17% and 51%, respectively. Multiple doses of pirtobrutinib (200 mg daily) further increased the AUC and C<span class=\"Sub\">max</span> of digoxin (sensitive P-gp substrate) up to 35% and 55%, respectively.</p><p><span class=\"Italics\">BCRP Substrates:</span> Multiple doses of pirtobrutinib (200 mg daily) increased the AUC and C<span class=\"Sub\">max</span> of rosuvastatin (sensitive BCRP substrate) by 140% and 146%, respectively.</p><p><span class=\"Italics\">CYP1A2 and CYP2C9 Substrates:</span> Pirtobrutinib did not have a clinically meaningful effect on the exposures of caffeine (sensitive CYP1A2 substrate) or S-warfarin (moderate sensitive CYP2C9 substrate).</p></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s59\"></a><a name=\"section-10.3.5.2\"></a><p></p><p class=\"First\"><span class=\"Italics\">In Vitro Studies</span></p><p>Cytochrome P450 (CYP) Enzymes: Pirtobrutinib inhibits CYP2C8, CYP2C9, CYP3A, CYP1A2, CYP2B6, CYP2C19, and CYP2D6. Pirtobrutinib induces CYP3A4, CYP3A5, CYP2B6, and CYP2C19.</p><p>Transporter Systems: Pirtobrutinib inhibits P-gp and BCRP, but not OAT1, OAT3, OCT1, OCT2, OATP1B1, OATP1B3, MATE1, or MATE2-K.  Pirtobrutinib is not a substrate of the hepatic transporters. Pirtobrutinib is a substrate of P-gp and BCRP, but not OCT1, OATP1B1, OATP1B3, or BSEP.</p></div></div></div></section>",
    "clinicalStudies": "<section class=\"Section\" data-sectioncode=\"34092-7\"><a name=\"s62\"></a><a name=\"section-12\"></a><p></p><h1>14 CLINICAL STUDIES</h1><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s63\"></a><a name=\"section-12.1\"></a><p></p><h2>14.1 Mantle Cell Lymphoma</h2><p class=\"First\">The efficacy of JAYPIRCA in patients with MCL was evaluated in BRUIN [NCT03740529], an open-label, international, multicohort, single-arm study of JAYPIRCA as monotherapy. Efficacy was based on 120 patients with MCL treated with JAYPIRCA who were previously treated with a BTK inhibitor. JAYPIRCA was given orally at a dose of 200 mg once daily and was continued until disease progression or unacceptable toxicity. Patients with active central nervous system lymphoma or allogeneic hematopoietic stem cell transplantation (HSCT) or CAR-T cell therapy within 60 days were excluded.</p><p>The median age was 71 years (range: 46 to 88 years); 79% were male; 78% were White, 14% Asian, 1.7% Black or African American. Seventy-eight percent of patients had the classic/leukemic variant of MCL, 12% had pleomorphic MCL, and 11% had blastoid MCL. The simplified Mantle Cell Lymphoma International Prognostic Index (sMIPI) score was low in 15%, intermediate in 59%, and high in 26% of patients. Patients received a median number of 3 prior lines of therapy (range: 1 to 9) with 93% having received 2 or more prior lines. All received 1 or more prior lines of therapy containing a BTK inhibitor; other prior therapies included chemoimmunotherapy in 88%, HSCT in 20%, lenalidomide in 18%, and CAR-T therapy in 9%. The most common prior BTK inhibitors received were ibrutinib (67%), acalabrutinib (30%), and zanubrutinib (8%). Patients may have received more than one prior BTK inhibitor; 83% of patients discontinued the last BTK inhibitor for refractory or progressive disease, 10% discontinued for toxicity, and 5% discontinued for other reasons.</p><p>Efficacy was based on overall response rate (ORR) and duration of response (DOR), as assessed by an independent review committee (IRC) using 2014 Lugano criteria. Efficacy results are shown in <a href=\"#t6\">Table 6</a>. Additionally, the Kaplan-Meier estimate for the DOR rate at 6 months was 65.3% (95% CI: 49.8, 77.1).</p><a name=\"t6\"></a><table width=\"100%\"><caption><span>Table 6: Efficacy Results per IRC in Patients with MCL Previously Treated with a BTK Inhibitor</span></caption><col align=\"left\" width=\"47.400%\"/><col align=\"left\" width=\"52.600%\"/><tfoot><tr class=\"First\"><td align=\"left\" colspan=\"2\" valign=\"top\"><p class=\"First Footnote\">CI, confidence interval; CR, complete response; DOR, duration of response; PR, partial response; NE, not estimable.</p></td></tr><tr><td align=\"left\" colspan=\"2\" valign=\"top\"><p class=\"First Footnote\"><span class=\"Sup\">a</span> PET-CT scans were utilized in response assessments (in 41% of patients), with the remainder being assessed by CT scans only.</p></td></tr><tr><td align=\"left\" colspan=\"2\" valign=\"top\"><p class=\"First Footnote\"><span class=\"Sup\">b</span> ORR using CT scan-based assessments in all patients was 48% (95% CI: 38, 57) and CR rate was 13%.</p></td></tr><tr class=\"Last\"><td align=\"left\" colspan=\"2\" valign=\"top\"><p class=\"First Footnote\"><span class=\"Sup\">c</span> Based on Kaplan-Meier estimation. Estimated median follow-up was 7.3 months.</p></td></tr></tfoot><tbody class=\"Headless\"><tr class=\"First\"><td align=\"left\" class=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><span class=\"Bold\">Outcome</span></td><td align=\"center\" class=\"Botrule Rrule Toprule\" valign=\"bottom\"><span class=\"Bold\">JAYPIRCA 200 mg once daily</span><br/><span class=\"Bold\">(N = 120)</span></td></tr><tr><td align=\"left\" class=\"Lrule Rrule\" valign=\"top\"><span class=\"Bold\">Overall Response Rate</span><span class=\"Bold\"><span class=\"Sup\">a,b</span></span></td><td align=\"center\" class=\"Rrule\" valign=\"top\"></td></tr><tr><td align=\"left\" class=\"Lrule Rrule\" valign=\"top\">     ORR, n</td><td align=\"center\" class=\"Rrule\" valign=\"top\">60 (50%)</td></tr><tr><td align=\"left\" class=\"Lrule Rrule\" valign=\"top\">      (95% CI, %)</td><td align=\"center\" class=\"Rrule\" valign=\"top\">41, 59</td></tr><tr><td align=\"left\" class=\"Lrule Rrule\" valign=\"top\">CR, n</td><td align=\"center\" class=\"Rrule\" valign=\"top\">15 (13%)</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">PR, n</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">45 (38%)</td></tr><tr><td align=\"left\" class=\"Lrule Rrule\" valign=\"top\"><span class=\"Bold\">Time to Response</span></td><td align=\"center\" class=\"Rrule\" valign=\"top\"></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Median (range), months</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">1.8 (0.8, 4.2)</td></tr><tr><td align=\"left\" class=\"Lrule Rrule\" valign=\"top\"><span class=\"Bold\">Duration of Response</span><span class=\"Bold\"><span class=\"Sup\">c</span></span></td><td align=\"center\" class=\"Rrule\" valign=\"top\"></td></tr><tr><td align=\"left\" class=\"Lrule Rrule\" valign=\"top\">     Number censored, n</td><td align=\"center\" class=\"Rrule\" valign=\"top\">36</td></tr><tr class=\"Last\"><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">     Median DOR, months (95% CI)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">8.3 (5.7, NE)</td></tr></tbody></table></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s64\"></a><a name=\"section-12.2\"></a><p></p><h2>14.2 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma</h2><p class=\"First\">The efficacy of JAYPIRCA in patients with CLL/SLL was evaluated in BRUIN [NCT03740529], an open-label, international, single-arm, multicohort study of JAYPIRCA as monotherapy. Efficacy was based on 108 patients with CLL/SLL treated with JAYPIRCA who were previously treated with at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor. JAYPIRCA was given orally at a dose of 200 mg once daily and was continued until disease progression or unacceptable toxicity. The trial required a platelet count ≥ 50 x 10<span class=\"Sup\">9</span>/L, absolute neutrophil count ≥ 0.75 x 10<span class=\"Sup\">9</span>/L, hepatic transaminases ≤ 2.5 times upper limit of normal (ULN), and an ECOG performance status of 0 to 2. The trial excluded patients with significant cardiovascular disease, major bleeding, uncontrolled or symptomatic arrhythmias, prolonged QTc interval, or need for a strong CYP3A inhibitor or inducer or strong P-gp inhibitor. Patients with active central nervous system (CNS) involvement by lymphoma or allogeneic hematopoietic stem cell transplantation (HSCT) within 60 days were excluded.</p><p>The median age was 68 years (range: 41 to 88 years); 69% were male; 89% were White, 4.6% Black or African American, 1.9% Asian and 1.9% were Hispanic or Latino. Baseline ECOG performance status was 0 or 1 in 91% of patients and 48% of patients had Rai stage III or IV disease. Among those patients with central testing available, 42% (37 of 88 patients) had a C481 BTK mutation, 54% (43 of 79 patients) had 17p deletion and/or TP53 mutation, 93% (77 of 83 patients) had unmutated IGHV, and 22% (16 of 72 patients) had 11q deletion. Patients received a median number of 5 prior lines of therapy (range: 2 to 11). The most common prior BTK inhibitors received were ibrutinib (97%), acalabrutinib (9%), and zanubrutinib (0.9%). Seventy-seven percent of patients discontinued the last BTK inhibitor for refractory or progressive disease, 13% discontinued for toxicity, and 10% discontinued for other reasons.</p><p>Efficacy was established based on overall response rate (ORR) and duration of response (DOR), as assessed by an independent review committee (IRC) using 2018 iwCLL criteria. Efficacy results are shown in <a href=\"#t7\">Table 7</a>. The median time to response was 3.7 months (range: 1.7, 27.9 months).</p><a name=\"t7\"></a><table width=\"100%\"><caption><span>Table 7: Efficacy Results per IRC in Patients with CLL/SLL Previously Treated with a BTK Inhibitor and a BCL-2 inhibitor</span></caption><col align=\"left\" width=\"47.350%\"/><col align=\"left\" width=\"52.650%\"/><tfoot><tr class=\"First\"><td align=\"left\" colspan=\"2\" valign=\"top\"><p class=\"First Footnote\">CI, confidence interval; PR, partial response.</p></td></tr><tr class=\"Last\"><td align=\"left\" colspan=\"2\" valign=\"top\"><p class=\"First Footnote\"><span class=\"Sup\">a</span> Based on Kaplan-Meier estimation. Estimated median follow-up was 15.7 months.</p></td></tr></tfoot><tbody class=\"Headless\"><tr class=\"First\"><td align=\"left\" class=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><span class=\"Bold\">Outcome</span></td><td align=\"center\" class=\"Botrule Rrule Toprule\" valign=\"bottom\"><span class=\"Bold\">JAYPIRCA 200 mg once daily</span><br/><span class=\"Bold\">(N = 108)</span></td></tr><tr><td align=\"left\" class=\"Lrule Rrule\" valign=\"top\"><span class=\"Bold\">Overall Response Rate</span></td><td align=\"center\" class=\"Rrule\" valign=\"top\"></td></tr><tr><td align=\"left\" class=\"Lrule Rrule\" valign=\"top\">ORR, n</td><td align=\"center\" class=\"Rrule\" valign=\"top\">78 (72%)</td></tr><tr><td align=\"left\" class=\"Lrule Rrule\" valign=\"top\">      (95% CI, %)</td><td align=\"center\" class=\"Rrule\" valign=\"top\">63, 80</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">PR, n</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">78 (72%)</td></tr><tr><td align=\"left\" class=\"Lrule Rrule\" valign=\"top\"><span class=\"Bold\">Duration of Response</span><span class=\"Bold\"><span class=\"Sup\">a</span></span></td><td align=\"center\" class=\"Rrule\" valign=\"top\"></td></tr><tr class=\"Last\"><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Median DOR, months (95% CI)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">12.2 (9.3, 14.7)</td></tr></tbody></table></div></section>",
    "howSupplied": "<section class=\"Section\" data-sectioncode=\"34069-5\"><a name=\"s65\"></a><a name=\"section-13\"></a><p></p><h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1><p class=\"First\"><span class=\"Underline\">How Supplied</span></p><p>JAYPIRCA tablets are supplied as follows:</p><table width=\"100%\"><col align=\"left\" width=\"21.125%\"/><col align=\"left\" width=\"24.075%\"/><col align=\"left\" width=\"33.675%\"/><col align=\"left\" width=\"21.125%\"/><tbody class=\"Headless\"><tr class=\"First\"><td align=\"left\" class=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><span class=\"Bold\">Tablet Strength</span></td><td align=\"left\" class=\"Botrule Rrule Toprule\" valign=\"bottom\"><span class=\"Bold\">Description</span></td><td align=\"left\" class=\"Botrule Rrule Toprule\" valign=\"bottom\"><span class=\"Bold\">Package Configuration</span></td><td align=\"left\" class=\"Botrule Rrule Toprule\" valign=\"bottom\"><span class=\"Bold\">NDC Number</span></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">50 mg</td><td align=\"left\" class=\"Botrule Rrule\" valign=\"top\">Blue, film coated, arc-triangle shaped tablets debossed with “Lilly 50” on one side and “6902” on the other side.</td><td align=\"left\" class=\"Botrule Rrule\" valign=\"top\">Bottle with child-resistant closure.<br/>Each bottle contains 30 tablets.</td><td align=\"left\" class=\"Botrule Rrule\" valign=\"top\">0002-6902-30</td></tr><tr class=\"Last\"><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">100 mg</td><td align=\"left\" class=\"Botrule Rrule\" valign=\"top\">Blue, film coated, round tablets debossed with “Lilly 100” on one side and “7026” on the other side.</td><td align=\"left\" class=\"Botrule Rrule\" valign=\"top\">Bottle with child-resistant closure.<br/>Each bottle contains 60 tablets.</td><td align=\"left\" class=\"Botrule Rrule\" valign=\"top\">0002-7026-60</td></tr></tbody></table><p><span class=\"Underline\">Storage and Handling</span></p><p>Store JAYPIRCA tablets at room temperature 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) ([see USP Controlled Room Temperature]).</p></section>",
    "useInSpecificPopulations": "<section class=\"Section\" data-sectioncode=\"43684-0\"><a name=\"s28\"></a><a name=\"section-8\"></a><p></p><h1>8 USE IN SPECIFIC POPULATIONS</h1><div class=\"Section\" data-sectioncode=\"42228-7\"><a name=\"s29\"></a><a name=\"section-8.1\"></a><p></p><h2>8.1 Pregnancy</h2><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s30\"></a><a name=\"section-8.1.1\"></a><p></p><p class=\"First\"><span class=\"Underline\">Risk Summary</span></p><p>Based on findings from animal studies, JAYPIRCA can cause fetal harm when administered to a pregnant woman. There are no available data on JAYPIRCA use in pregnant women to evaluate for a drug-associated risk. In an animal reproduction study, administration of pirtobrutinib to pregnant rats during organogenesis resulted in adverse developmental outcomes, including structural abnormalities, altered fetal growth, and embryo-fetal mortality, at maternal exposures approximately 3-times those in patients at the recommended daily dose of 200 mg (see Data). Advise pregnant women of the potential risk to a fetus.</p><p>The background risk in the U.S. general population of major birth defects is 2% to 4% and of miscarriage is 15% to 20% of clinically recognized pregnancies.</p></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s31\"></a><a name=\"section-8.1.2\"></a><p></p><p class=\"First\"><span class=\"Underline\">Data</span></p><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s32\"></a><a name=\"section-8.1.2.1\"></a><p></p><p class=\"First\"><span class=\"Italics\">Animal Data</span></p><p>In an embryo-fetal development study in rats, pregnant animals were administered oral doses of pirtobrutinib at up to 500 mg/kg twice daily during the period of organogenesis. Doses ≥ 375 mg/kg twice daily caused decreased fetal body weights and increased incidence of malformations and variations in the urinary tract (including absent or abnormal ureters and kidneys), reproductive tract (malpositioned ovaries and misshapen uterus), and bone (misshapen sternebrae). At 500 mg/kg twice daily, total resorption was observed. At 375 mg/kg twice daily in rats, the maternal systemic exposures (AUC) were approximately 3 times the human exposure at 200 mg once daily.</p></div></div></div><div class=\"Section\" data-sectioncode=\"77290-5\"><a name=\"s33\"></a><a name=\"section-8.2\"></a><p></p><h2>8.2 Lactation</h2><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s34\"></a><a name=\"section-8.2.1\"></a><p></p><p class=\"First\"><span class=\"Underline\">Risk Summary</span></p><p>There are no data on the presence of pirtobrutinib in human milk or the effects on the breastfed child or milk production. Because of the potential for serious adverse reactions in the breastfed child, advise women not to breastfeed during treatment with JAYPIRCA and for one week after the last dose.</p></div></div><div class=\"Section\" data-sectioncode=\"77291-3\"><a name=\"s35\"></a><a name=\"section-8.3\"></a><p></p><h2>8.3 Females and Males of Reproductive Potential</h2><p class=\"First\">Based on findings from animal studies, JAYPIRCA can cause fetal harm when administered to a pregnant woman <span class=\"Italics\">[see Use in Specific Populations (<a href=\"#s29\">8.1</a>)].</span></p><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s36\"></a><a name=\"section-8.3.1\"></a><p></p><p class=\"First\"><span class=\"Underline\">Pregnancy Testing</span></p><p>Verify pregnancy status in females of reproductive potential prior to initiating JAYPIRCA.</p></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s37\"></a><a name=\"section-8.3.2\"></a><p></p><p class=\"First\"><span class=\"Underline\">Contraception</span></p><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s38\"></a><a name=\"section-8.3.2.1\"></a><p></p><p class=\"First\"><span class=\"Italics\">Females</span></p><p>Advise females of reproductive potential to use effective contraception during treatment with JAYPIRCA and for one week after the last dose.</p></div></div></div><div class=\"Section\" data-sectioncode=\"34081-0\"><a name=\"s39\"></a><a name=\"section-8.4\"></a><p></p><h2>8.4 Pediatric Use</h2><p class=\"First\">Safety and effectiveness of JAYPIRCA have not been established in pediatric patients.</p></div><div class=\"Section\" data-sectioncode=\"34082-8\"><a name=\"s40\"></a><a name=\"section-8.5\"></a><p></p><h2>8.5 Geriatric Use</h2><p class=\"First\">Of the patients with MCL who received the 200 mg dose of JAYPIRCA in BRUIN, 93 (78%) were 65 years of age and older and 39 (33%) were 75 years and older <span class=\"Italics\">[see Clinical Studies (<a href=\"#s63\">14.1</a>)]</span>. Clinical studies of JAYPIRCA did not include sufficient numbers of patients with MCL who were less than 65 years of age to determine whether older patients respond differently from younger adult patients. Of the patients with CLL/SLL who received the 200 mg once daily dose of JAYPIRCA in BRUIN, 68 (63%) were 65 years of age and older and 21 (19%) were 75 years and older <span class=\"Italics\">[see Clinical Studies (<a href=\"#s64\">14.2</a>)]</span>. No overall differences in effectiveness were observed between younger and older patients.</p><p>In the pooled safety population in patients with hematologic malignancies, 401 (68%) were 65 years of age and older, while 154 (26%) were 75 years of age and older. Patients aged 65 years and older experienced higher rates of Grade 3 and higher adverse reactions and serious adverse reactions compared to patients who were less than 65 years of age.</p></div><div class=\"Section\" data-sectioncode=\"88828-9\"><a name=\"s41\"></a><a name=\"section-8.6\"></a><p></p><h2>8.6 Renal Impairment</h2><p class=\"First\">Severe renal impairment (eGFR15-29 mL/min) increases pirtobrutinib exposure <span class=\"Italics\">[see Clinical Pharmacology (<a href=\"#s48\">12.3</a>)]</span>. Reduce the JAYPIRCA dosage in patients with severe renal impairment <span class=\"Italics\">[see Dosage and Administration (<a href=\"#s6\">2.3</a>)]</span>. No dosage adjustment of JAYPIRCA is recommended in patients with mild (60-89 mL/min) or moderate (30-59 mL/min) renal impairment.</p></div><div class=\"Section\" data-sectioncode=\"88829-7\"><a name=\"s42\"></a><a name=\"section-8.7\"></a><p></p><h2>8.7 Hepatic Impairment</h2><p class=\"First\">No dosage adjustment of JAYPIRCA is recommended in patients with mild hepatic impairment (total bilirubin ≤ upper limit of normal (ULN) and aspartate aminotransferase (AST) &gt; ULN or total bilirubin &gt; 1 to 1.5 × ULN and any AST), moderate hepatic impairment (total bilirubin &gt; 1.5 to 3 × ULN and any AST), or severe hepatic impairment (total bilirubin &gt; 3 × ULN and any AST) <span class=\"Italics\">[see Clinical Pharmacology (<a href=\"#s48\">12.3</a></span>)<span class=\"Italics\">].</span></p></div></section>",
    "description": "<section class=\"Section\" data-sectioncode=\"34089-3\"><a name=\"s43\"></a><a name=\"section-9\"></a><p></p><h1>11 DESCRIPTION</h1><p class=\"First\">Pirtobrutinib is a kinase inhibitor. It is an orally available, small molecule ATP-competitive inhibitor of BTK. The active pharmaceutical ingredient is pirtobrutinib with the molecular formula C<span class=\"Sub\">22</span>H<span class=\"Sub\">21</span>F<span class=\"Sub\">4</span>N<span class=\"Sub\">5</span>O<span class=\"Sub\">3</span> and a molecular weight of 479.44 g/mol. The chemical name for pirtobrutinib is 5-amino-3-{4-[(5-fluoro-2-methoxybenzamido)methyl]phenyl}-1-[(2<span class=\"Italics\">S</span>)-1,1,1-trifluoropropan-2-yl]-1<span class=\"Italics\">H</span>-pyrazole-4-carboxamide.</p><p><a name=\"f01\"></a><img alt=\"Chemical Structure\n\" src=\"jaypirca-uspi-chem-str-v1.jpg\"/></p><p>Pirtobrutinib is a white to practically white to yellow to brown solid. The aqueous solubility of pirtobrutinib is considered practically insoluble, or insoluble, across the pH 1 to pH 7 range.</p><p>Pirtobrutinib tablets are supplied as 50 mg or 100 mg film-coated, debossed tablets for oral administration. Each tablet contains inactive ingredients of croscarmellose sodium, hypromellose acetate succinate, lactose monohydrate, magnesium stearate, microcrystalline cellulose and silicon dioxide. The tablet film coating material contains FD&amp;C Blue #2, hypromellose, titanium dioxide and triacetin.</p></section>",
    "nonclinicalToxicology": "<section class=\"Section\" data-sectioncode=\"43680-8\"><a name=\"s60\"></a><a name=\"section-11\"></a><p></p><h1>13 NONCLINICAL TOXICOLOGY</h1><div class=\"Section\" data-sectioncode=\"34083-6\"><a name=\"s61\"></a><a name=\"section-11.1\"></a><p></p><h2>13.1 Carcinogenesis, mutagenesis, impairment of fertility</h2><p class=\"First\">Carcinogenicity studies have not been conducted with pirtobrutinib.</p><p>Pirtobrutinib was not mutagenic in a bacterial mutagenicity (Ames) assay. Pirtobrutinib was aneugenic in <span class=\"Italics\">in vitro</span> micronucleus assays using human peripheral blood lymphocytes. Pirtobrutinib was not genotoxic in an <span class=\"Italics\">in vivo</span> rat bone marrow micronucleus assay at doses up to 2000 mg/kg.</p><p>Studies to assess the effects of pirtobrutinib on fertility have not been conducted. In repeat-dose toxicity studies of up to 3-months duration conducted with pirtobrutinib in rats and dogs, no effects on male or female reproductive organs were identified.</p></div></section>",
    "mechanismOfAction": "<section class=\"Section\" data-sectioncode=\"43679-0\"><a name=\"s45\"></a><a name=\"section-10.1\"></a><p></p><h2>12.1 Mechanism of action</h2><p class=\"First\">Pirtobrutinib is a small molecule, noncovalent inhibitor of BTK. BTK is a signaling protein of the B-cell antigen receptor (BCR) and cytokine receptor pathways. In B-cells, BTK signaling results in activation of pathways necessary for B-cell proliferation, trafficking, chemotaxis, and adhesion. Pirtobrutinib binds to wild type BTK and BTK harboring C481 mutations, leading to inhibition of BTK kinase activity. In nonclinical studies, pirtobrutinib inhibited BTK-mediated B-cell CD69 expression and inhibited malignant B-cell proliferation. Pirtobrutinib showed dose-dependent anti-tumor activities in BTK wild type and BTK C481S mutant mouse xenograft models.</p></section>",
    "contraindications": "<section class=\"Section\" data-sectioncode=\"34070-3\"><a name=\"s10\"></a><a name=\"section-4\"></a><p></p><h1>4 CONTRAINDICATIONS</h1><p class=\"First\">None.</p></section>",
    "highlights": {
      "dosageAndAdministration": "<div><ul class=\"Disc\"><li>Recommended dosage: 200 mg orally once daily; swallow whole with water, with or without food. Do not cut, crush, or chew tablets. (<a href=\"#s4\">2.1</a>)</li><li>Manage toxicity using treatment interruption, dosage reduction, or discontinuation. (<a href=\"#s5\">2.2</a>)</li><li>Reduce dose in patients with severe renal impairment. (<a href=\"#s6\">2.3</a>, <a href=\"#s41\">8.6</a>)</li></ul></div>"
    }
  }
}